Last reviewed · How we verify
Epirubicin, Paclitaxel
Epirubicin, Paclitaxel is a Chemotherapy combination (anthracycline + taxane) Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently in Phase 3 development for Breast cancer (early-stage and metastatic), Gastric cancer, Ovarian cancer.
Epirubicin and paclitaxel are chemotherapy agents that work together to inhibit cancer cell division and induce apoptosis through different mechanisms.
Epirubicin and paclitaxel are chemotherapy agents that work together to inhibit cancer cell division and induce apoptosis through different mechanisms. Used for Breast cancer (early-stage and metastatic), Gastric cancer, Ovarian cancer.
At a glance
| Generic name | Epirubicin, Paclitaxel |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | Chemotherapy combination (anthracycline + taxane) |
| Target | Topoisomerase II (epirubicin); β-tubulin/microtubules (paclitaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epirubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand separation, while paclitaxel is a microtubule stabilizer that prevents microtubule depolymerization. Together, this combination targets rapidly dividing cancer cells through complementary mechanisms of action, commonly used in breast cancer treatment regimens.
Approved indications
- Breast cancer (early-stage and metastatic)
- Gastric cancer
- Ovarian cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Peripheral neuropathy
- Cardiotoxicity
- Fatigue
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (PHASE2)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (PHASE2)
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (PHASE2)
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (PHASE2)
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epirubicin, Paclitaxel CI brief — competitive landscape report
- Epirubicin, Paclitaxel updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI
Frequently asked questions about Epirubicin, Paclitaxel
What is Epirubicin, Paclitaxel?
How does Epirubicin, Paclitaxel work?
What is Epirubicin, Paclitaxel used for?
Who makes Epirubicin, Paclitaxel?
What drug class is Epirubicin, Paclitaxel in?
What development phase is Epirubicin, Paclitaxel in?
What are the side effects of Epirubicin, Paclitaxel?
What does Epirubicin, Paclitaxel target?
Related
- Drug class: All Chemotherapy combination (anthracycline + taxane) drugs
- Target: All drugs targeting Topoisomerase II (epirubicin); β-tubulin/microtubules (paclitaxel)
- Manufacturer: Chinese Academy of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer (early-stage and metastatic)
- Indication: Drugs for Gastric cancer
- Indication: Drugs for Ovarian cancer
- Compare: Epirubicin, Paclitaxel vs similar drugs
- Pricing: Epirubicin, Paclitaxel cost, discount & access